This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is Sangamo Therapeutics, Inc. (SGMO) Outperforming Other Medical Stocks This Year?
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session
by Zacks Equity Research
Sangamo Therapeutics (SGMO) shares rose more than 14% in the last trading session, amid huge volumes.
Recession is Coming! Not
by Kevin Cook
Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk
Pfizer (PFE) Collaborates With Sangamo for Gene Therapy
by Zacks Equity Research
Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.
Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer
by Arpita Dutt
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
4 Biotech Stocks Ready to Crush the Market in 2018
by Zacks Equity Research
The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.
3 Buy-Ranked Biotech Stocks That Soared in 2017
by Benjamin Rains
The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.
Why Sangamo Therapeutics (SGMO) Could Be Positioned for a Surge
by Zacks Equity Research
Sangamo Therapeutics, Inc. (SGMO) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
These 5 Stocks Have Popped More Than 100% Since Trump's Win
by Swarup Gupta
With tax cuts close to becoming law, it makes sense to pick stocks that have posted stellar performances since Trump's win.
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
5 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
4 Biotech Stocks to Better Your Financial Health This Winter
by Zacks Equity Research
The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.
Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?
by Zacks Equity Research
GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
by Zacks Equity Research
Sangamo Therapeutics (SGMO) shares rose nearly 14% in the last trading session, amid huge volumes.
Best Sector ETF of Q3 and its Top-Performing Stocks
by Sweta Killa
Inside the top performing stocks of top U.S.-focused ETF of Q3.
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
Why These 4 Biotech Stocks May Not Lose Momentum Soon
by Zacks Equity Research
The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.
Sangamo Therapeutics Initiates Dosing in Hemophilia A Study
by Zacks Equity Research
Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525.
What You See, and What You Get: The Neurology of Perception
by Kevin Cook
While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.
Will Sangamo Therapeutics (SGMO) Crush Estimates at Its Next Earnings Report?
by Zacks Equity Research
Sangamo Therapeutics (SGMO) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
3 Biotech Stocks That More than Doubled Year to Date
by Arpita Dutt
Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.
Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).